Cynata is a regenerative medicine company. Its Cymerus technology can produce vast quantities of Mesenchymal Stem Cells from a single blood donation. Cymerus is now in Phase 1 in acute Graft vs Host Disease. Japan’s Fujifilm has optioned this indication.
Cynata Therapeutics (ASX:CYP) is making steady progress: Interview with Dr. Kilian Kelly
Cynata Therapeutics (ASX:CYP) is making steady progress: Interview with Dr. Kilian Kelly
Date: 13/10/2025
On 13 October 2025 we spoke to Dr Kilian Kelly, CEO of Cynata Therapeutics (ASX:CYP), about the three clinical studies currently ongoing that will read out data in the coming months, the earlier clinical data which has already pointed to efficacy, and the competitive advantage which its stem cells have over competing products.
